Four key dynamics—coverage and access, average sales price, provider net cost recovery, and patient cost impact—affect the biosimilar market and pose a risk to the long-term sustainability of the infused biosimilar system, said Scott Biggs, the director of supplier services for IQVIA, at the NASP 2024 Annual Meeting & Expo, in Nashville, Tenn.
“Biosimilars that have been on the market for several years have begun to erode the sales of their reference